Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Trinidad & Tobago Wellness Today.
Press releases published on August 4, 2025
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug …
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
– $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue reported by …
Dunham House to Partner with CrossMed Healthcare Staffing
OMAHA, Neb., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Dunham House, a first-of-its-kind, transformational initiative for combat-wounded veterans in need of long-term residential-centered care for their wounds, will partner with Omaha-based CrossMed Healthcare …
ACGME International Expands to Indonesia, Accredits New Programs in Japan and Lebanon
Chicago, Illinois, US, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ACGME International (ACGME-I) is proud to announce the beginning of its accreditation activities in Indonesia as six institutions have achieved Initial Accreditation. The newly accredited Sponsoring …
Avis aux médias: L’Hôpital Shriners pour enfants Canada invite les médias à son tournoi de golf annuel
Quoi : L’Hôpital Shriners pour enfants Canada convie les représentants des médias à une occasion spéciale de photos et d’entrevues dans le cadre de son tournoi de golf annuel, qui se tiendra au club Summerlea Golf …
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007 PTG-007, an autologous cell therapy will be administered to 150 high-risk children aged 3–18, including a placebo-controlled arm. A parallel study presented to …
Healthcare Workforce Management Market Surges Amid Drive for Operational Efficiency and Cost Reduction
Boston, Aug. 04, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Global Healthcare Workforce Management System Market” is expected to grow from $1.9 billion in 2024 to $3.1 billion by the end of 2029, at a compound annual …
Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight
New York, USA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight The neuroendocrine prostate cancer treatment space will experience …
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
Data Demonstrate that Sana’s Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to Genetically Modify and Transplant Pancreatic …
Freya Pharma Solutions Announces Launch of Phase II Clinical Dose-Response Study testing its LybridoTM Concept Targeting Female Sexual Dysfunction
www.freyapharmasolutions.com Study evaluates Lybrido™’s Dual-Action therapy for Female Sexual Dysfunction Innovative clitoral blood flow measurement technique aims to objectively quantify treatment efficacy of two dose-combinations ALETTA Pivotal Study …
PracticeLink Announces Strategic Partnership with 3RNET
ST. LOUIS and HINTON, West Virginia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- PracticeLink, the nation’s most trusted physician recruitment resource and home of the most widely used online physician job board, is pleased to announce a strategic partnership with …
Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models
MENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of a study published in Nature Methods describing a new, comprehensive truth- …
Capsa Healthcare Acquires BlueBin to Advance Intelligent Clinical Supply Management
COLUMBUS, Ohio, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Capsa Healthcare, a leader in healthcare workflow and supply management solutions, today announced the acquisition of BlueBin, a recognized innovator in Kanban-based supply chain systems and predictive …
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval
Primary focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both no significant toxicity and superior PFS and …
NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on …
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety, cytokine, and efficacy data suggest a strong potential …
Noom Launches Microdose GLP-1 Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program
70% of Noom members receiving microdoses of GLP-1 with lifestyle support report no side effects, while experiencing significant weight loss and overall health gains The program addresses all three major barriers to bending the obesity curve in the US: …
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective …
Oral Care Market to Hit $53.29 Billion by 2030 | 6.4% CAGR Growth Forecast | MarketsandMarkets™.
Delray Beach, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The global oral care market, valued at US$34.97 billion in 2024 stood at US$37.21 billion in 2025 and is projected to advance at a resilient CAGR of 6.4% from 2025 to 2030, culminating in a forecasted …